Background-Hypertrophic cardiomyopathy is a genetically heterogeneous myocardial disease with >1000 causal variants identified. Nonunique variants account for disease in many families. We sought to characterize nonunique variants in Australian families and determine whether they arise from common ancestral mutations or recurrent mutation events. 
H ypertrophic cardiomyopathy (HCM) is a common inherited myocardial disease characterized by unexplained hypertrophy of the left ventricle. [1] [2] [3] Most patients with HCM have a relatively benign clinical course, whereas others experience major adverse events, including heart failure and sudden cardiac death. 4, 5 HCM is primarily associated with an autosomal dominant inheritance pattern, and a pathogenic variant is identified overall in 30% to 50% of patients. [6] [7] [8] Over 1000 causal variants have been described in at least 8 sarcomere or sarcomere-related genes although >80% of variants are found in 2 genes: MYBPC3 (myosin-binding protein-C) and MYH7 (myosin heavy chain 7). 9, 10 Historically, causal variants were described as largely family-specific or private; however, wider access to genetic testing has inevitably led to a decline in the number of novel variants reported. 8 
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A major recent advance in genetic testing has been the increased stringency of variant interpretation criteria. The American College of Medical Genetics and Genomics recently released a guidelines document to better delineate evidence required to assign causation to rare variants. 11 Presence of a variant in additional unrelated cases with the same phenotype is now one of the key criteria that can help to determine whether a rare variant is pathogenic. This is especially important because most families are not sufficiently powered to perform informative segregation studies. Therefore, an effort to catalogue and describe families has enormous potential to provide additional supportive information, impacting on clinical care of families worldwide.
A common haplotype among families with HCM carrying an identical variant implies that a single mutation event occurred in a common ancestor, whereas recurrent variants tend to occur on different haplotypes. Overall, relatively few founder HCM variants have been reported, and they are predominantly in MYBPC3, which account for a large proportion of patients in some countries (Table 1) . For example, nearly one fourth of HCM cases in The Netherlands share a haplotype with a c.2373dupG variant in MYBPC3. 12 In contrast, the most common genetic cause of HCM elsewhere is the c.1504C>T, p.Arg502Trp variant in MYBPC3, which is found on multiple different haplotypes. 24 To date, no common ancestral variants have been reported in Australian patients with HCM. The Australian population of 24 million is of multiethnic origin, with historical migration from many regions, including Europe, the United Kingdom, Asia-Pacific, and North America. Population data report that ≈1 in 4 Australians were born overseas, illustrating the degree of multiculturalism present. We report the occurrence of variants found in multiple Australian families with HCM and determine whether they arise from common ancestral mutations or recurrent mutation events.
Methods

Participants
We recruited an index patient from apparently unrelated families with HCM who attended the Genetic Heart Diseases Clinic, Royal Prince Alfred Hospital, Sydney, and had undergone research-based or clinical genetic testing. Family members with available DNA were included. Participants were clinically assessed, including clinical history, physical examination, and by investigations, including electrocardiography and echocardiography. Family history was collected by a cardiac genetic counselor as per clinic practice. The diagnostic criterion for HCM was a maximum left ventricular wall thickness of ≥15 mm in the absence of loading conditions that could otherwise explain the extent of hypertrophy. 25 Dutch probands with HCM and their available family members, who had variants in common with Australian HCM families, were included. Studies were approved by the Sydney Local Health District Review Committee and University Medical Center Utrecht, University Medical Center Groningen, and the Academic Medical Center Amsterdam institutional review committee, and all subjects gave informed consent. 
Genetic Analyses and Variant Classification
Haplotype Analysis
Haplotypes were constructed using polymorphic dinucleotide repeat markers within and flanking MYBPC3 (D11S1344, MYBPC3-CA, and D11S4109) or MYH7 (D14S990, MYOI, MYOII, and D14S972; Table I in the Data Supplement). Microsatellites were polymerase chain reaction amplified using standard conditions with a fluorescently labeled primer at 95°C for 2 minutes, followed by 30 cycles of 95°C for 30 seconds, 58°C for 30 seconds, and 72°C for 1 minute. Polymerase chain reaction products mixed with GeneScan500 LIZ size standard (Life Technologies) were separated on an ABI 3730xl DNA analyzer, and alleles were sized using Peak Scanner software v1.0 (Life Technologies). To establish the phase of alleles, haplotypes were directly determined with cosegregation analysis of family members. For probands without available family members, haplotypes were inferred if the available allele and causal mutation combinations matched a directly determined disease-associated haplotype.
Polymorphism Information Content
Polymorphisms are highly informative for haplotype studies if any individual chosen at random is likely to be heterozygous for the marker. Polymorphism information content (PIC) is a statistical measure of the expected fraction of informative offspring. PIC values range from 0 to 1; a marker with only 1 allele has a PIC value of 0 and a marker with infinite alleles has a PIC value of 1. PIC values of dinucleotide repeat markers (Table I in 
Results
Genetic Testing
Genetic testing was performed on 467 unselected and apparently unrelated families with HCM. A likely pathogenic or Figure 1 ). There were 95 distinct LP/P variants and most were unique to 1 family (n=63; 66%). However, when considering only LP/P variants, more than half of all families had a nonunique variant (n=122; 66%; Table II in the Data Supplement). The most common LP/P variants were in MYBPC3: c.1504C>T, p.Arg502Trp (13 families); c.2373dupG, p.Trp792Valfs*41 (8 families); and c.2864_2865delCT, p.Pro955Argfs*95 (7 families). Thirteen LP/P variants alone accounted for 78 (42%) families, and all have been reported multiple times in non-Australian families with HCM (Table 2) .
Haplotype Analysis
We performed haplotype analysis on 126 individuals from 70 Australian families with HCM (median number of individuals haplotyped per family=1, range=1-7) to determine whether nonunique variants represent multiple independent mutation events or single ancestral mutations. We focused on the 13 variants found in >3 families (Table II and Figure 2B and 2C). In contrast to the recurrent variants, 2 variants were found on 1 haplotype in 6 families each, supportive of a single mutation inherited from a common ancestor: MYBPC3 c.1928-2A>G; MYH7 c.2681A>G (Figure 2A and 2D ). All 12 families with ancestral mutations were of European descent.
To determine the origins of the 13 most common Australian HCM variants, we performed haplotype analysis on 14 individuals from 5 Dutch families (median number of individuals haplotyped per family=3, range=2-4). The recurrent MYBPC3 c.2373dupG variant is a founder mutation in The Netherlands, however, has occurred multiple times to cause HCM in Australian families. Two Australian patients shared the same MYBPC3 haplotype as a Dutch patient with this founder mutation, suggesting a shared ancestry, and both Australian patients were of European descent ( Figure 2B ). We next compared the haplotypes of 3 Dutch and 7 Australian families with the MYBPC3 c.2864_2865delCT variant. The 3 Dutch families carried 2 different haplotypes and neither matched the haplotypes of Australian families, further demonstrating that c.2864_2865delCT is a recurrent mutation ( Figure 2C) . Finally, the single haplotype found in 6 Australian families with the c.1928-2A>G variant was compared with that in a Dutch family with this variant, and the alleles at markers D11S1344 and MYBPC3-CA were shared, whereas the D11S4109 allele size was 181 bp in Australian families and 177 bp in the Dutch family (Figure 2A ).
Mutation Mechanisms
Seven of the 9 (78%) recurrent single nucleotide variants were C to T transitions at a CpG dinucleotide (Table 2) , whereas neither of the 2 ancestral variants were C to T transitions at a CpG dinucleotide. To determine whether recurrent transition single-nucleotide variants occur more often than expected at CpG sites, the number of CpG transitions at unique and recurrent sites were compared. Twenty-four of 48 (50%) unique single-nucleotide variants were C to T transitions at a CpG dinucleotide compared with 7 of 9 recurrent variants, and this was not significant (P=0.153). Table 3 shows the clinical and demographic characteristics of Australian probands with common ancestral and recurrent variants. Whereas the total number of probands in each genotype was relatively small, probands with ancestral variants were diagnosed at a similar age and had a similar maximum left ventricular wall thickness as those with recurrent variants and included families with a history of sudden cardiac death. None of the comparisons of clinical features reached statistical significance. 
Genotype-Phenotype Associations
Discussion
Discovery of the genetic origins of human disease forms a fundamental basis for improved understanding of disease pathogenesis and phenotype development. In this study, an LP/P variant was identified in 40% of Australian families with HCM. The majority of families with a causal variant identified have an LP/P variant in common with another family. Two ancestral variants and 11 recurrent variants account for 17% of all Australian families with HCM and are prevalent among non-Australian patients. Highly recurrent variants The origins and variety of LP/P variants in HCM pose a challenge for classification of pathogenicity, and both local and global networks that share genetic and phenotype data will be helpful to define clinically relevant variants. Our genetic test yield of 40% is in line with other recent large unselected cohorts of HCM. 8, 27 The yield is lower compared with historical studies, which may reflect an increased stringency of variant classification criteria, our improved appreciation of rare variation in the general population and more widespread uptake of genetic testing in individuals with less severe HCM. Additionally, this study is limited to variants identified in 8 established causal HCM genes. The most common single genetic cause of HCM in Australian patients is the c.1504C>T, p.Arg502Trp variant in MYBPC3, which was found on 3 different haplotypes in 13 (2.8%) families. Because 2 haplotypes differ by only 2 bp at marker D11S4109, the c.1504C>T variant may have arisen from 3 independent mutation events or from 2 mutation events with a new haplotype formed either by a D11S4109 allele size change or a recombination event. Nevertheless, the prevalence and recurrence of the c.1504C>T variant in our cohort is consistent with other published cohorts of primarily European patients with HCM. 24 Australia has a multicultural population, with only 54% of Australians declaring in the 2011 census that both parents were born in Australia, and historically, immigration from European countries has been high. 28 We found 2 variants, MYBPC3 c.1928-2A>G and MYH7 c.2681A>G, on the same haplotype in 6 families of European ancestry, and both likely represent ancestral mutations that originate from European ancestors. The c.1928-2A>G ancestral variant in MYBPC3 was haplotyped in a Dutch patient with this variant, and the alleles at D11S1344 and an intragenic marker matched the Australian haplotype, whereas the D11S4109 allele was different. Therefore, we were unable to establish whether the Australian and Dutch patients share a common ancestral mutation on a haplotype that has undergone a recombination event or if these variants represent 2 independent mutations.
The identification of the MYH7 c.2681A>G variant on the same haplotype in 6 seemingly unrelated Australian families was unexpected given the low number of reported founder variants in MYH7. To date, the only founder variants in MYH7 that have been reported are MYH7 p.Ala797Thr and MYH7 p.Arg403Trp, which have both been identified in a South African cohort. 23 When compared with diseasecausing variants in MYBPC3, MYH7 variants seem more likely to cause earlier disease onset and greater disease severity, which may contribute to this trend. 24 The MYH7 c.2681A>G variant is well described in HCM and has been reported in at least 6 additional families in North America, the United Kingdom, and Canada. [29] [30] [31] We were unable to determine if the original mutation event occurred in a common Australian ancestor or was introduced to Australia through migration.
The c.2373dupG variant in MYBPC3 is a founder variant in The Netherlands 12 and was found in 8 Australian families on multiple haplotypes. Two Australian families with European ancestry shared the Dutch founder haplotype, implying that they have a common ancestor. A further 2 Australian families have this variant on a haplotype that differs by only 1 dinucleotide repeat at marker D11S4109 and may represent an additional transmission of the Dutch founder mutation. Delayed disease onset and incomplete penetrance may explain why founder variants that cause HCM, such as MYBPC3 c.2373dupG, escape negative selection pressures to cause disease across many generations. 12, 16, 18 There were 11 common recurrent variants, 7 of which are C to T transitions at a CpG dinucleotide. The cytosine of a CpG dinucleotide is often methylated and can spontaneously deaminate, producing a T:G mismatch, which can lead to a C to T transition mutation. 32 All of the 7 common C to T transitions found in Australian patients have collectively been reported 33, 34 No such sequences were apparent flanking the indels, and the mechanism leading to the recurrent indels remains to be determined.
The clinical significance of establishing whether a variant is unique, recurrent, or a common ancestral mutation is important. These findings assist in determining the pathogenicity of variants specific to a phenotype, such as HCM. Correlation of the variant with phenotype features, such as disease penetrance and severity of disease, remains poorly understood in HCM. Given the small number of probands with HCM within each mutation group (Table 3) , no definitive conclusions could be drawn comparing clinical features, such as age at diagnosis, severity of left ventricular hypertrophy, or sudden death events. Larger studies focused on a single variant, such as the c.1504C>T variant in the MYBPC3 gene, have elucidated more data on disease penetrance and severity. 18, 24 This study highlights the importance of sharing genetic test results to facilitate variant classification and explore possible genotype-phenotype relationships. The majority of families with a causal variant identified carry a nonunique variant that has been identified in patients around the world. The low mutation yield reported here and by others 8 emphasizes that we have much to learn about the genetic causes of HCM. The increasing use of next-generation sequencing techniques, such as whole-exome and whole-genome sequencing, will help to advance this area. Our study further highlights the importance of readily available and accessible genetic and phenotype data in human genetic diseases, such as HCM. Both international and national initiatives are important. A local network of genetic testing providers who share genotype and phenotype data, such as the Australian Cardiac Genetic Testing Network, 35 is a useful adjunct to the multidisciplinary approach of establishing the pathogenicity of variants in the local community. Global networks of genetic testing providers promoting public reporting of curated variants, such as ClinVar, will be invaluable for interpretation of clinically relevant variants that are rare among families with HCM and other inherited diseases.
